ArticleFrontiers in medicine2026
Clinical outcomes of effectiveness and safety in cataract patients implanted with the novel hybrid extended depth-of-focus intraocular lens AM2UH: a prospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: AM2UH was a novel bifocal hybrid extend the depth of focus (EDF) intraocular lens (IOL). This study is to evaluate the effectiveness and safety by comparing it with a monofocal IOL (AW-UV). Methods: A prospective, comparative, single-center study. 37 patients (37 eyes) were implanted with novel hybrid EDF IOL model AM2UH. 36 patients (36 eyes) were implanted with monofocal IOL model AW-UV. At 6 months postoperatively, the visual acuity (uncorrected and distance corrected), defocus curves, refractive outcomes, contrast sensitivity, questionnaires of visual quality were assessed and compared between 2 groups. Results: Compared to AW-UV, AM2UH showed non-inferior monocular corrected distance visual acuity ( Conclusion: AM2UH IOL is an effective and safe EDF IOL that offers satisfactory intermediate vision and distance vision, improves near vision, and delivers an extended visual range while maintaining favorable visual quality. Clinical trial registration: Identifier: MR-50-25-086616.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.